Xeris Biopharma Holdings (XERS) Assets Average (2021 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Assets Average came in at $387.8 million in Q1 2026, up 21.46% YoY from $319.3 million in Q1 2025, and up 2.9% on a QoQ basis from $376.9 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Assets Average (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 6 years of Assets Average data on file, last reported at $387.8 million in Q1 2026.
- Quarterly Assets Average rose 21.46% year-over-year to $387.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $387.8 million (up 21.46% YoY) and the FY2025 annual result came in at $353.3 million, up 9.44% from the prior year.
- Assets Average climbed to $387.8 million in Q1 2026, from $376.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $387.8 million in Q1 2026 to a low of $310.8 million in Q3 2022.
- A 5-year average of $333.5 million and a median of $326.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average surged 48.65% — and 2025, when it decreased 3.14%.
- Tracing XERS's Assets Average over 5 years: stood at $323.8 million in 2022, then rose by 0.44% to $325.2 million in 2023, then fell by 0.96% to $322.1 million in 2024, then climbed by 17.01% to $376.9 million in 2025, then gained by 2.9% to $387.8 million in 2026.
- The last three Assets Average figures came in at $387.8 million (Q1 2026), $376.9 million (Q4 2025), and $352.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 5.97 Bn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 401.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 401.96 Mn |
| Mar 31, 2026 | 387.77 Mn |
| Dec 31, 2025 | 376.86 Mn |
| Sep 30, 2025 | 352.44 Mn |
| Jun 30, 2025 | 325.07 Mn |
| Mar 31, 2025 | 319.26 Mn |
| Dec 31, 2024 | 322.08 Mn |
| Sep 30, 2024 | 326.42 Mn |
| Jun 30, 2024 | 334.17 Mn |
| Mar 31, 2024 | 329.61 Mn |
| Dec 31, 2023 | 325.19 Mn |
| Sep 30, 2023 | 328.28 Mn |
| Jun 30, 2023 | 325.07 Mn |
| Mar 31, 2023 | 332.94 Mn |
| Dec 31, 2022 | 323.77 Mn |
| Sep 30, 2022 | 310.82 Mn |
| Jun 30, 2022 | 328.12 Mn |
| Mar 31, 2022 | 320.99 Mn |
| Dec 31, 2021 | 217.81 Mn |